16 Oct Lung Cancer Alliance’s 2nd Annual Screening and Care Conference
On September 24 and 25, 2016, I was able to attend the Lung Cancer Alliance’s 2nd Annual Screening and Care Conference held in Washington DC. I was also asked to participate as a panelist discussing “Taking your program to the next level.”
I learned that many hospitals and lung screening centers are just now beginning to start a lung program and need help and direction. It was reassuring to be part of a group of healthcare professionals who have goals like mine, to find cancer at an early stage. Many different levels of participants attended from health educators, social workers, nurses of different levels of education, and physicians.
When meeting with the vendors, one vendor product caught my attention. Oncimmune http://oncimmune.co.uk/ EarlyCDT® -Lung test. Low dose CT screening is the only NCCN, US task force and other associations approved screening test. However, if a barrier is lack of a screening facility or they do not meet their insurance guidelines, a blood test can be order by the PCP to help stratify risk. This can also be performed if a smaller nodule is found and discussion around determining if more aggressive tissue follow up or regular imaging follow up needs to occur. The test checks for autoantibodies that may be present in the blood before signs and symptoms of lung cancer are known. If moderate or high levels of these autoantibodies are found, then a more aggressive follow up needs to occur. If low risk results, then follow image guided recommendations. The blood test is being reimbursed by Medicare and most insurance companies.
There is another blood test that once you find a nodule: http://gensignia.com/Home.aspx. Gensignia is a micro RNA signature classifier.
Another test is by Veracyte, Perceta. Percepta is a bronchial genomic classifier that is beneficial after the bronchoscope yields are inconclusive. It utilizes bronchial epithelial cells. https://www.veracyte.com/
There are many genomic tests available once a cancer is detected but these are 3 newer technology tests out now to help identify lung cancers earlier.
For a disease that has such a low rate of early detection, I am totally open to your thoughts on these and any other early detection methods. Let me know what works in your centers and if you have any other tests that help you decide a patient’s pathway algorithm. Please email me at Kim.Parham@LungCancerSolution.com or call at 615-972-2787.